Close
RNS Number : 8859Y
Alliance Pharma PLC
06 January 2020
 

 

For immediate release

6 January 2020

 

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

 

Block Listing Six Monthly Return

 

Name of applicant:

ALLIANCE PHARMA PLC

Names of schemes:

a)     The Alliance Pharma plc Approved Share Option Plan 2005

b)    The Alliance Pharma plc Share Option Plan 2006

c)     The Alliance Pharma plc Company Share Option Plan 2015

Period of return:

From:

28 June 2019

To:

28 December 2019

Number of securities originally admitted at date of admission:

25,000,000 ordinary shares of 1p each

28 June 2017

Balance of unallotted securities under schemes from previous return:

a)     983,541

b)    15,345,688

a)     1,226,097

Plus:  The amount by which the block schemes have been increased since the date of the last return (if any increase has been applied for):

a)     Nil

b)    Nil

c)     Nil

Less:  Number of securities issued/allotted under schemes during period:

a)     434,467

b)    9,234,354

c)     588,621

Equals:  Balance under schemes not yet issued/allotted at end of period:

a)     549,074

b)    6,111,334

c)     637,576

         

 

Name of contact:

Chris Chrysanthou, Company Secretary

Telephone number of contact:

Tel. +44 (0)1249 705166

 

For further information:

 

Buchanan                                                                                                        + 44 (0) 20 7466 5000

Mark Court / Hannah Ratcliff

 

Numis Securities Limited                                                                              + 44 (0) 20 7260 1000

Nominated Adviser: Freddie Barnfield / Huw Jeremy

Corporate Broking: James Black

 

Investec Bank plc                                                                                           +44 (0) 20 7597 5970

Corporate Finance: Daniel Adams / Ed Thomas

Corporate Broking: Patrick Robb / Tejas Padalkar

 

Notes to editors:

 

About Alliance Pharma

 

Alliance, founded in 1998, is an international specialty pharmaceutical group based in Chippenham, Wiltshire, UK. The Group has sales in more than 100 countries worldwide via direct sales, joint ventures and a wide network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Group continues to explore opportunities to expand its product portfolio.

 

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRKKABPNBKDADK